Market Access 360 Insights (MA360i) is a strategic intelligence platform focused on helping diagnostics companies navigate clinical evidence requirements and payer expectations for high-impact, innovative tests. We use AI-driven tools and expert analysis to synthesize clinical data, guideline alignment, and payer coverage trends.
2. Featured Report Title: Clinical Evidence & Coverage Implications for Minimal Residual Disease (MRD) Testing in Solid Tumors Summary: This report delivers a clear, actionable view of the clinical and policy landscape surrounding MRD testing for solid tumors—a rapidly advancing area in precision oncology. It includes: •Synthesis of clinical studies, professional guidelines, and payor policies •Coverage trends and evidence gaps •Strategic implications for market access and reimbursement planning Format: 1-page infographic Access Link: https://ma360i.com/download-mrd-testing-infographic/
SAN CARLOS, Calif., Sept. 8, 2025 /PRNewswire-PRWeb/ --
1. Overview of MA360i
Market Access 360 Insights (MA360i) is a strategic intelligence platform focused on helping diagnostics companies navigate clinical evidence requirements and payer expectations for high-impact, innovative tests. We use AI-driven tools and expert analysis to synthesize clinical data, guideline alignment, and payer coverage trends.
2. Featured Report
Title: Clinical Evidence & Coverage Implications for Minimal Residual Disease (MRD) Testing in Solid Tumors
Summary:
This report delivers a clear, actionable view of the clinical and policy landscape surrounding MRD testing for solid tumors—a rapidly advancing area in precision oncology. It includes:
- Synthesis of clinical studies, professional guidelines, and payor policies
- Coverage trends and evidence gaps
- Strategic implications for market access and reimbursement planning
Format: 1-page infographic
Access Link: https://ma360i.com/download-mrd-testing-infographic/
3. Target Audience
- Diagnostics & molecular test developers
- Market access, medical affairs, and reimbursement teams
- Payers, policy advisors, and health economists
- Investors and strategists in precision oncology
4. Key Messages
- MRD in solid tumors is emerging as a key category for early cancer detection, recurrence monitoring, and treatment optimization.
- Payers are actively shaping policies, but evidence thresholds remain a barrier.
- This resource helps diagnostic innovators align development with real-world access needs.
5. Available Assets
- 1-page infographic summary (PDF): https://ma360i.com/download-mrd-testing-infographic/
- Sample slides for partner use (on request)
- Expert commentary (available for interviews or contributed articles)
6. Contact
Contact Name: Rick Nida
Title: CEO
Company: Market Access 360 Insights, Inc. (MA360i)
Email: [email protected]
LinkedIn: https://www.linkedin.com/in/4ricknida/
Media Contact
Rick Nida, Market Access 360 Insights, Inc. (MA360i), 1 6504642902, [email protected], https://ma360i.com/evidence-assessment-coverage-implications/
SOURCE Market Access 360 Insights, Inc. (MA360i)
Share this article